# Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

> **NCT02354534** · PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 30 (actual)

## Conditions studied

- Cervical Intraepithelial Neoplasia Grade 2/3
- High-risk HPV (Any Strain)

## Interventions

- **DRUG:** Artesunate Suppositories

## Key facts

- **NCT ID:** NCT02354534
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2018-07
- **Final completion:** 2018-11-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02354534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02354534, "Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02354534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*